In the VEGFA-amplified PDTX model of OSA, sorafenib resulted in reduced tumor volume compared to vehicle, whereas in another PDTX model without VEGFA-amplified OSA, there was no benefit from sorafenib treatment. Here, VEGFA is linked to neoplasm.